Roivant's pill Lisraya succeeds in trials for eye disease uveitis
Roivant says its pill Lisraya worked in two late-stage trials for non-infectious uveitis. The eye disease can lead to blindness. Patients on the drug went a median of more than 48 weeks before treatment failure. Those on a placebo lasted 12 weeks. Roivant plans to seek approval in the first half of next year.
Where this came from. 2 outlets reported this. We read them, then wrote the sixty words above.